Do I need a prescription for Suxamethonium chloride 100mg/2ml solution for injection ampoules?

Suxamethonium chloride 100mg/2ml solution for injection ampoules is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

Suxamethonium chloride 100mg/2ml solution for injection ampoules

Prescription only

Requires a prescription from a doctor or prescriber

Injection

100mg/2ml

Parenteral

Oral liquids

General anaesthesia

Active ingredients:

Suxamethonium

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 15.01.05

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC M03AB01

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Suxamethonium

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Suxamethonium

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Suxamethonium

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Suxamethonium

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

4 branded products available

4 productsShow details

4 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Suxamethonium on the MHRA register

Suxamethonium chloride 100mg/2ml solution for injection ampoules

Advanz Pharma

Suxamethonium chloride 100mg/2ml solution for injection ampoules

Martindale Pharmaceuticals Ltd

Anectine 100mg/2ml solution for injection ampoules

Aspen Pharma Trading Ltd

Discontinued

Suxamethonium chloride 100mg/2ml solution for injection ampoules

A A H Pharmaceuticals Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Therapeutically similar medicines

10 similarShow details

Suxamethonium chloride 10mg/2ml solution for injection pre-filled syringes

Injection

10mg/2ml

Same therapeutic group

Suxamethonium chloride 100mg/2ml solution for injection pre-filled syringes

Injection

100mg/2ml

Same therapeutic group

Rocuronium bromide 50mg/5ml solution for injection pre-filled syringes

Injection

50mg/5ml

Same BNF section

Rocuronium bromide 100mg/10ml solution for injection pre-filled syringes

Injection

100mg/10ml

Same BNF section

Remimazolam 50mg powder for solution for injection vials

Injection

50mg

Same BNF section

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Suxamethonium

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(1)

Specialist neonatal respiratory care for babies born preterm (NG124)

NG124

NICE guideline

Updated Apr 2019

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Suxamethonium

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

35914511000001106

dm+d ID

35914511000001106

VTM (Virtual Therapeutic Moiety)

777622006

VMP (Virtual Medicinal Product)

35914511000001106

BNF code

15010500

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

M03AB01

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

1 found

Half-life

Not available

Mechanism

Succinylcholine is a depolarizing neuromuscular blocker, meaning it causes a pro…

Food interactions

None known

Human targets

3 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Half-life

47 seconds

The mean half-life of elimination following intravenous administration is 47 seconds.
[A233225]

Volume of distribution

1 mg/k

At intravenous doses of 1 mg/kg and 2 mg/kg in 14 patients, the mean apparent volumes of distribution were 16.4…

Metabolism

Succinylcholine is rapidly metabolized by plasma cholinesterase in the bloodstream to succinylmonocholine, which is then further hydrolyzed (albeit more slowly) to succinic acid and choline.
[L32828]…

Elimination

10%

Approximately 10% of an administered dose is excreted unchanged in the urine.
[L32828]

Clearance

1 mg/k

The mean in vivo plasma clearance of succinylcholine following an intravenous dose of 1 mg/kg in 18 patients was approximately 4.17…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups.[A19054] It has been widely used for over 50 years,[A299] most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short medical procedures requiring brief periods of muscle relaxation.[L9004]

Properties:

solid

Avg. mass: 290.40 Da

DrugBank indication

Succinylcholine is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
[L9004]

Also known as(28)

2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)

Dicholine succinate

Succinocholine

Succinoylcholine

Succinylbischoline

Succinylcholine

Succinyldicholine

Suxamethonium

Dosage forms(29)

Injection, solution (Intramuscular; Intravenous; Parenteral) — 20 mg/1mL

Powder, for solution (Intravenous) — 500 mg / pck

Liquid (Intravenous) — 20 mg / mL

Solution (Intravenous) — 40.00 mg

Injection (Intravenous) — 103 mg/2mL

Solution (Intravenous) — 40 mg/ml

Injection, powder, for solution (Intramuscular; Intravenous) — 100 mg

Injection, solution (Parenteral) — 0.1 g/5ml

Molecular properties(18)

Drug interactions(1180)

Known interactions with other medications. Always consult a healthcare professional.

Buprenorphine

Moderate

DB00921

Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.

Check this interaction

Hydrocodone

Moderate

DB00956

Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Succinylcholine may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.

Check this interaction

Mirtazapine

Moderate

DB00370

Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.

Check this interaction

Orphenadrine

Moderate

DB01173

Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.

Check this interaction

Pramipexole

Moderate

DB00413

Succinylcholine may increase the sedative activities of Pramipexole.

Check this interaction

Ropinirole

Moderate

DB00268

Succinylcholine may increase the sedative activities of Ropinirole.

Check this interaction

Rotigotine

Moderate

DB05271

Succinylcholine may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Succinylcholine.

Check this interaction

Sodium oxybate

Unknown severity

DB09072

The risk or severity of CNS depression can be increased when Succinylcholine is combined with Sodium oxybate.

Check this interaction

Suvorexant

Moderate

DB09034

Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Tapentadol

Moderate

DB06204

Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.

Check this interaction

Thalidomide

Moderate

DB01041

Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Morphine

Unknown severity

DB00295

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Morphine.

Check this interaction

Codeine

Unknown severity

DB00318

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Codeine.

Check this interaction

Hydromorphone

Unknown severity

DB00327

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Hydromorphone.

Check this interaction

Meperidine

Unknown severity

DB00454

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Meperidine.

Check this interaction

Oxycodone

Unknown severity

DB00497

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Oxycodone.

Check this interaction

Butorphanol

Unknown severity

DB00611

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Butorphanol.

Check this interaction

Dextropropoxyphene

Unknown severity

DB00647

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dextropropoxyphene.

Check this interaction

Pentazocine

Unknown severity

DB00652

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Pentazocine.

Check this interaction

Naltrexone

Unknown severity

DB00704

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Naltrexone.

Check this interaction

Sufentanil

Unknown severity

DB00708

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Sufentanil.

Check this interaction

Alfentanil

Unknown severity

DB00802

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Alfentanil.

Check this interaction

Fentanyl

Unknown severity

DB00813

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Fentanyl.

Check this interaction

Nalbuphine

Unknown severity

DB00844

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Nalbuphine.

Check this interaction

Levorphanol

Unknown severity

DB00854

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Levorphanol.

Check this interaction

Remifentanil

Unknown severity

DB00899

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Remifentanil.

Check this interaction

Diphenoxylate

Unknown severity

DB01081

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Diphenoxylate.

Check this interaction

Oxymorphone

Unknown severity

DB01192

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Oxymorphone.

Check this interaction

Dezocine

Unknown severity

DB01209

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dezocine.

Check this interaction

Levacetylmethadol

Unknown severity

DB01227

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Levacetylmethadol.

Check this interaction

Methadyl acetate

Unknown severity

DB01433

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Methadyl acetate.

Check this interaction

Dihydroetorphine

Unknown severity

DB01450

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dihydroetorphine.

Check this interaction

Diamorphine

Unknown severity

DB01452

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Diamorphine.

Check this interaction

Bezitramide

Unknown severity

DB01459

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Bezitramide.

Check this interaction

Ethylmorphine

Unknown severity

DB01466

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Ethylmorphine.

Check this interaction

Etorphine

Unknown severity

DB01497

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Etorphine.

Check this interaction

Dextromoramide

Unknown severity

DB01529

The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dextromoramide.

Check this interaction

Showing 50 of 1180 interactions

Toxicity & overdose

Overdosage of succinylcholine is likely to extend the neuromuscular blockade beyond the time needed for surgery. Symptoms are likely to be consistent with its therapeutic effects, although more pronounced, and may therefore include skeletal muscle weakness, decreased respiratory reserve, low tidal volume, or apnea. Treatment of succinylcholine overdose involves airway and respiratory support until recovery of normal respiration is assured.
[L9004]

Depending on the extent of the overdose, the characteristic depolarizing (i.e.

Phase I) neuromuscular blockade may switch to resemble more closely a non-depolarizing (i.e. Phase II) neuromuscular blockade.
[L9004]
This occurs primarily when succinylcholine is given over a prolonged period of time or with particularly large doses, and may result in significant respiratory muscle paralysis or weakness.

How it works

Mechanism of action

Succinylcholine is a depolarizing neuromuscular blocker, meaning it causes a prolonged period of membrane depolarization in order to exert its therapeutic effects. It binds to the post-synaptic cholinergic receptors found on motor endplates, thereby inducing first transient fasciculations followed by skeletal muscle paralysis.[A233250]

Pharmacodynamics

Succinylcholine's neuromuscular blockade takes effect within 60 seconds of intravenous administration and lasts between four to six minutes.[A19054] Similar to acetylcholine, it binds to cholinergic receptors of the motor endplate to induce membrane depolarization and, eventually, muscle paralysis, which may be maintained for as long as an adequate concentration of succinylcholine remains at the receptor site.[L32828] Succinylcholine has no direct action on smooth or cardiac muscle, nor does it appear to act on pre-synaptic or ganglionic acetylcholine receptors.[A34369] The paralysis induced by succinylcholine has been described as "progressive", first involving the muscles of the face and glottis, then the intercostals and diaphragm, then followed by other skeletal muscles.[L32828]

Succinylcholine has no effect on consciousness or pain threshold, and must therefore be used in conjunction with adequate anesthesia.[L9004] There have been rare reports of the development of acute rhabdomyolysis with hyperkalemia - resulting in ventricular dysrhythmias, cardiac arrest, and death - after the intravenous administration of succinylcholine to apparently healthy pediatric patients who were subsequently found to have undiagnosed skeletal myopathy (most frequently Duchenne's muscular dystrophy).[L9004] Infants or children experiencing seemingly idiopathic cardiac arrest soon after the administration of succinylcholine should therefore be treated immediately for hyperkalemia. Given that patients may not present with any apparent risk factors, the use of succinylcholine in pediatric patients should be restricted to emergency intubation or other situations in which a suitable alternative is unavailable.[L9004]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Half-life

The mean half-life of elimination following intravenous administration is 47 seconds.
[A233225]

Volume of distribution

At intravenous doses of 1 mg/kg and 2 mg/kg in 14 patients, the mean apparent volumes of distribution were 16.4 ± 14.7 and 5.6 ± 6.8 mL/kg, respectively.
[A233235]

Metabolism

Succinylcholine is rapidly metabolized by plasma cholinesterase in the bloodstream to succinylmonocholine, which is then further hydrolyzed (albeit more slowly) to succinic acid and choline.
[L32828]

Route of elimination

Approximately 10% of an administered dose is excreted unchanged in the urine.
[L32828]

Clearance

The mean in vivo plasma clearance of succinylcholine following an intravenous dose of 1 mg/kg in 18 patients was approximately 4.17 ± 2.37 L/min.
[A233220]

Drug targets(3)

Proteins and enzymes this drug interacts with in the body

Neuronal acetylcholine receptor subunit beta-4

BE0009927

CHRNB4

agonist

Specific functionacetylcholine receptor activity

Cellular location

Synaptic cell membrane

General function & pharmacology

Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, cation permeability, and binding to allosteric modulators .
PMID:20881005 PMID:31488329 PMID:8663494 PMID:8906617 PMID:9203638

CHRNB4 forms heteropentameric neuronal acetylcholine receptors with CHRNA2, CHRNA3 and CHRNA4, as well as CHRNA5 and CHRNB3 as accesory subunits .
PMID:11118490 PMID:20881005 PMID:8663494

CHRNA3:CHRNB4 being predominant in neurons of the autonomic ganglia, it is known as ganglionic nicotinic receptor .
PMID:31488329
CHRNA3:CHRNB4 or CHRNA3:CHRNA5:CHRNB4 play also an important role in the habenulo-interpeduncular tract, modulating the mesolimbic dopamine system and affecting reward circuits and addiction (By similarity). Hypothalamic CHRNA3:CHRNB4 nAChR activation by nicotine leads to activation of POMC neurons and a decrease in food intake (By similarity)

Muscarinic acetylcholine receptor M2

BE0000560

CHRM2

agonist

Specific functionarrestin family protein binding

Cellular location

Cell membrane

General function & pharmacology

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol

Muscarinic acetylcholine receptor M3

BE0000045

CHRM3

agonist

Specific functionacetylcholine binding

Cellular location

Cell membrane

General function & pharmacology

Metabolizing enzymes(1)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

BCHECholinesterase

substrate

Scientific references(7)

Jonsson M., Dabrowski M., Gurley D.A., Larsson O., Johnson E.C., Fredholm B.B., Eriksson L.I.

Activation and Inhibition of Human Muscular and Neuronal Nicotinic Acetylcholine Receptors by Succinylcholine.

Anesthesiology

2006104(4):724-733. doi: 10.1097/00000542-200604000-00017

PMID: 16571968 DOI: 10.1097/00000542-200604000-00017

Alvarellos M.L., McDonagh E.M., Patel S., McLeod H.L., Altman R.B., Klein T.E.

PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics.

Pharmacogenet Genomics

2015 Dec25(12):622-30. doi: 10.1097/FPC.0000000000000170

PMID: 26398623 DOI: 10.1097/FPC.0000000000000170

Kato M., Shiratori T., Yamamuro M., Haga S., Hoshi K., Matsukawa S., Jalal I.M., Hashimoto Y.

Comparison between in vivo and in vitro pharmacokinetics of succinylcholine in humans.

Journal Anesth

1999 Oct 3013(4):189-92. doi: 10.1007/s005400050055

PMID: 14564614 DOI: 10.1007/s005400050055

Torda T.A., Graham G.G., Warwick N.R., Donohue P.

Pharmacokinetics and pharmacodynamics of suxamethonium.

Anaesth Intensive Care

1997 Jun25(3):272-8. doi: 10.1177/0310057X9702500312

PMID: 9209610 DOI: 10.1177/0310057X9702500312

Martyn J., Durieux M.E.

Succinylcholine.

Anesthesiology

2006104(4):633-634. doi: 10.1097/00000542-200604000-00004

PMID: 16571955 DOI: 10.1097/00000542-200604000-00004

Hoshi K., Hashimoto Y., Matsukawa S.

Pharmacokinetics of succinylcholine in man.

Tohoku Journal Experimental Medicine

1993 Aug170(4):245-50. doi: 10.1620/tjem.170.245

PMID: 8122251 DOI: 10.1620/tjem.170.245

Hager H.H., Burns B.

Succinylcholine Chloride.

doi: 10

31003/uspnf_m78520_05_01

PMID: 29763160 DOI: 10.31003/uspnf_m78520_05_01

ATC classification(1 code)

ATC M03AB01

Affected organisms(1)

Humans and other mammals

International brands(2)

Salt forms(2)

Succinylcholine chloride(DBSALT000206)

Succinylcholine chloride dihydrate(DBSALT003046)

Experimental properties(1)

External resources(2)

RxList Drugs.com

Protein Data Bank entries(3)

2ha2

2ha6

8f6z

Commercial products(79)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Succinylcholine

Matched from: Suxamethonium

DB00202

CAS number

306-40-1

UNII (FDA)

J2R869A8YF

InChI Key (molecular fingerprint)

AXOIZCJOOAYSMI-UHFFFAOYSA-N

Synonym match

95% confidence

Additional database identifiers

Drugs Product Database (DPD)

8833

ChEBI

45652

PubChem Compound

5314

PubChem Substance

46506023

KEGG Compound

C07546

ChemSpider

5123

BindingDB

50061568

PharmGKB

PA451522

PDB

SCK

Therapeutic Targets Database

DAP001132

IUPHAR

4004

Guide to Pharmacology

4004

Wikipedia

Suxamethonium_chloride

ChEMBL

CHEMBL703

ZINC

ZINC000001530820

RxCUI

10154

HUGO Gene Nomenclature Committee (HGNC)

HGNC:13800

GenAtlas

CHRNA10

GeneCards

CHRNA10

GenBank Gene Database

AJ278118

GenBank Protein Database

12053839

IUPHAR

470

Guide to Pharmacology

470

UniProtKB

Q9GZZ6

UniProt Accession

ACH10_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1956

GenAtlas

CHRNA2

GeneCards

CHRNA2

GenBank Gene Database

U62431

GenBank Protein Database

1458110

IUPHAR

463

Guide to Pharmacology

463

UniProtKB

Q15822

UniProt Accession

ACHA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1957

GeneCards

CHRNA3

GenBank Gene Database

M86383

GenBank Protein Database

177898

Guide to Pharmacology

464

UniProtKB

P32297

UniProt Accession

ACHA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1958

GenAtlas

CHRNA4

GeneCards

CHRNA4

GenBank Gene Database

L35901

GenBank Protein Database

755648

IUPHAR

465

Guide to Pharmacology

465

UniProtKB

P43681

UniProt Accession

ACHA4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1959

GeneCards

CHRNA5

GenBank Gene Database

M83712

GenBank Protein Database

177926

UniProtKB

P30532

UniProt Accession

ACHA5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:15963

GeneCards

CHRNA6

GenBank Gene Database

U62435

GenBank Protein Database

1458118

Guide to Pharmacology

467

UniProtKB

Q15825

UniProt Accession

ACHA6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1960

GenAtlas

CHRNA7

GeneCards

CHRNA7

GenBank Gene Database

X70297

GenBank Protein Database

496607

IUPHAR

468

Guide to Pharmacology

468

UniProtKB

P36544

UniProt Accession

ACHA7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:14079

GenAtlas

CHRNA9

GeneCards

CHRNA9

GenBank Gene Database

AJ243342

GenBank Protein Database

6688136

IUPHAR

469

Guide to Pharmacology

469

UniProtKB

Q9UGM1

UniProt Accession

ACHA9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1962

GenAtlas

CHRNB2

GeneCards

CHRNB2

GenBank Gene Database

X53179

GenBank Protein Database

32017

IUPHAR

472

UniProtKB

P17787

UniProt Accession

ACHB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1963

GeneCards

CHRNB3

GenBank Gene Database

U62438

GenBank Protein Database

1458124

UniProtKB

Q05901

UniProt Accession

ACHB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1964

GeneCards

CHRNB4

GenBank Gene Database

U62439

GenBank Protein Database

1458126

UniProtKB

P30926

UniProt Accession

ACHB4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1951

GenAtlas

CHRM2

GeneCards

CHRM2

GenBank Gene Database

M16404

GenBank Protein Database

177990

IUPHAR

Guide to Pharmacology

UniProtKB

P08172

UniProt Accession

ACM2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1952

GenAtlas

CHRM3

GeneCards

CHRM3

GenBank Gene Database

X15266

GenBank Protein Database

32324

IUPHAR

Guide to Pharmacology

UniProtKB

P20309

UniProt Accession

ACM3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:983

GenAtlas

BCHE

GeneCards

BCHE

GenBank Gene Database

M32391

GenBank Protein Database

1311630

Guide to Pharmacology

2471

UniProtKB

P06276

UniProt Accession

CHLE_HUMAN

International reference pricing

3 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.22/ml

To $2.08/ml

Quelicin 20 mg/ml vial

$0.22/ml

Quelicin 100 mg/ml vial

$1.20/ml

Succinylcholine-ns 140 mg/7 ml

$2.08/ml

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

Patent information

1 active patent

12295932

United States

Approved 2 Nov 2021 · Expires 2 Nov 2041

15y 7m

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Suxamethonium chloride 100mg/2ml solution for injection ampoules

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

British National Formulary

NICE clinical guidance(1)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Half-life

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
4

Chemical identifiers

Succinylcholine

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Suxamethonium chloride 100mg/2ml solution for injection ampoules

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(1)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Half-life

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science4

Chemical identifiers

Succinylcholine

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Deep science
4